Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density: Esther study | Zendy

Nada Vujasinović-Stupar | Zendy; Nataša Milić | Zendy; Ljiljana Petrović-Rackov | Zendy; Nenad Prodanović | Zendy; Milena Mijailović-Ivković | Zendy; Zoran Grujic | Zendy; Stevan Bukovic | Zendy; Snežaovković | Zendy; Katarina Pasalic-Simic | Zendy; Vera Petrović | Zendy; Dragan Vukasinovic | Zendy; Gordana Peruničić | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density: Esther study

Author(s) -

Nada Vujasinović-Stupar,

Nataša Milić,

Ljiljana Petrović-Rackov,

Nenad Prodanović,

Milena Mijailović-Ivković,

Zoran Grujic,

Stevan Bukovic,

Snežaovković,

Katarina Pasalic-Simic,

Vera Petrović,

Dragan Vukasinovic,

Gordana Peruničić

Publication year - 2010

Publication title -

srpski arhiv za celokupno lekarstvo

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.135

H-Index - 17

eISSN - 2406-0895

pISSN - 0370-8179

DOI - 10.2298/sarh1002056v

Subject(s) - medicine , osteoporosis , bone mineral , concomitant , adverse effect , bisphosphonate , menopause , incidence (geometry) , surgery , physics , optics

Osteoporosis usually affects post-menopausal women. Treatment is individualized and requires an approach that will provide long-term compliance to prevent fractures. Studies conducted so far suggest inadequate compliance and persistence in weekly bisphosphonate treatment (under 43% after a year of treatment). Ibandronate, as a powerful bisphosphonate, has made it possible for the first time to treat osteoporosis with a single tablet per month.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research